PANDEMIC INFLUENZA PROGRAM
The National Strategy for Pandemic Influenza (November 2005) designated the Department of Health and Human Services (HHS) as the lead agency for public health preparedness and medical response to a probable or actual influenza pandemic. The Biomedical Advanced Research and Development Authority (BARDA), within HHS' Office of the Assistant Secretary for Preparedness and Response (ASPR), was established by The Pandemic and All-Hazards Preparedness Act (PAHPA, December 2006) to facilitate the research, development, and acquisition of medical countermeasures for chemical, biological, radiological, and nuclear threats, as well as for emerging or re-emerging infectious diseases like pandemic influenza. PAHPA was reauthorized in 2013 by the signing of Pandemic and All Hazards Preparedness Reauthorization Act (PAHPRA).
BARDA uses a strategic portfolio approach to develop and acquire a broad array of medical countermeasures for pandemic influenza. This includes developing vaccines, therapeutics, diagnostics, and non-pharmaceutical countermeasures for influenza preparedness and building and sustaining facilities for their domestic manufacturing.
The Pandemic Influenza programs within BARDA span several critical focus areas:
- Cell-Based Vaccines
- Antigen-Sparing Vaccines
- Recombinant-Based Vaccines
- Influenza Vaccine Manufacturing Improvement Initiative
- BARDA Universal Influenza Vaccines
BARDA Pandemic Influenza Vaccine Stockpile Program
BARDA Influenza Vaccine Manufacturing Infrastructure Program
BARDA Influenza Therapeutics Program
BARDA Influenza Diagnostics and Respiratory Devices Program
BARDA International Influenza Vaccine Manufacturing Capacity Building Program